培菲康联合乳杆菌治疗老年细菌性阴道病

目的 观察口服培菲康联合阴道用乳杆菌治疗老年细菌性阴道病的疗效。方法 选取2016年1月至2017年8月我院就诊的114例老年细菌性阴道病患者,随机分为联合治疗组、乳杆菌组和对照组各38例,联合治疗组给予口服培菲康联合阴道用乳杆菌活菌胶囊,乳杆菌组给予阴道用乳杆菌活菌胶囊,对照组给予阴道用甲硝唑栓。观察三组患者治疗效果、复发情况以及阴道pH的变化。结果 联合治疗组和乳杆菌组的治疗总有效率均明显高于对照组(χ2=4.290 3、4.069 9,均P<0.05),联合治疗组治疗有效的患者3、6个月内复发率均明显低于对照组(χ2=5.526 0、6.983 7,均P<0.05),联合治疗组治疗有效的患者6个月内复发率明显低于乳杆菌组(χ2=5.499 4,P<0.05),治疗6个月后联合治疗组阴道pH值明显低于乳杆菌组和对照组(t=3.736 1、4.353 8,均P<0.05)。结论 口服培菲康联合阴道用乳杆菌治疗老年细菌性阴道病,不仅能提高近期疗效,对于长期预防也有明显的效果。     

乳杆菌活菌胶囊在配合治疗产后滴虫性阴道炎中的价值

目的探讨应用乳杆菌活菌胶囊在配合治疗产后滴虫性阴道炎中的作用。方法将90例患滴虫性阴道炎的产后妇女随机分为2组,研究组应用甲硝唑400 mg,每日2次,连服7 d,同时每日晚塞1粒乳杆菌活菌胶囊入阴道,连用10 d;对照组应用甲硝唑400 mg,每日2次,连服7 d。2组患者14 d后复查并检查白带常规,对其临床治愈率、白带清洁度、pH进行比较。30 d后随访检查滴虫性阴道炎复发情况。结果用药后研究组治愈率高于对照组,2组差异有统计学意义(P<0.05);研究组、对照组pH均有降低,但研究组pH低于对照组,2组差异有统计学意义(P<0.05);用药后研究组阴道清洁度I、II度比率高于对照组,研究组复发率低于对照组,差异均有统计学意义(P<0.05)。结论产妇应用乳杆菌活菌胶囊配合治疗滴虫性阴道炎可提高治愈率,改善阴道微环境并降低复发率。     

乳杆菌活菌胶囊预防细菌性阴道病复发的临床效果

目的 评价乳杆菌活菌胶囊(商品名:定君生)预防细菌性阴道病复发的临床效果.方法 将2011年10月至2012年5月深圳市南山区妇幼保健院妇科门诊140例细菌性阴道病患者随机分为2组,研究组在细菌性阴道病患者治愈后给予乳杆菌活菌胶囊巩固治疗,阴道上药,1粒/(次·d),连用10 d;对照组仅给予常规治疗.结果 研究组复发率明显低于对照组,差异具有统计学意义(P＜0.05).结论 乳杆菌活菌胶囊能改善及重建阴道微生态平衡,从而有效减少细菌性阴道病的复发.     

乳杆菌对全子宫切除术后阴道微生态的影响

目的 分析甲硝唑阴道准备联合全子宫切除术对患者阴道微生态的影响及乳杆菌的应用价值。 方法 采用前瞻性分析,收集2015年1月至2018年5月我院符合本研究相关标准并行腹腔镜全子宫切除的患者100例为研究对象,患者术前均用甲硝唑进行阴道准备。采用随机数字表将入选患者分为2组,每组50例。观察组患者在术后2个月时采用乳杆菌活菌胶囊阴道给药,1次/d,2粒/次,10 d/疗程,共3个疗程;对照组不处理。观察2组患者术前、术后2个月、术后3个月时阴道乳杆菌数量、pH值、菌群多样性、菌群密集度分级差异,同时对比观察组与对照组患者治疗前后阴道乳杆菌检出率、阴道菌群失衡率、pH值、FSFI分值。 结果 (1)100例患者术后2个月时阴道乳杆菌数量、pH值、菌群多样性、菌群密度分级均显著减少,以Ⅰ级为主;术后3个月时以Ⅳ级为主。(2)与治疗前相比,两组患者阴道乳杆菌检出率均升高,阴道菌群失衡率均降低,pH值均降低,FSFI分值均升高(均P0.05);治疗后观察组患者阴道乳杆菌检出率高于对照组,阴道菌群失衡率、pH值低于对照组,FSFI分值高于对照组(均P2=3.78,P=0.022)。 结论 甲硝唑阴道准备联合腹腔镜全子宫切除术患者术后阴道微生态环境被破坏,尤其以术后2个月最为明显,给予乳杆菌干预能促使被破坏的阴道微生态环境恢复正常,减少术后细菌性阴道病的发生,值得应用和推广。     

乳杆菌活菌胶囊联合甲硝唑栓治疗细菌性阴道病的疗效及预防复发作用

目的探讨乳杆菌活菌胶囊联合甲硝唑栓治疗细菌性阴道病的疗效及预防复发作用。方法将88例细菌性阴道病患者的随机分为观察组和对照组。观察组患者予以乳杆菌活菌胶囊和甲硝唑栓联合治疗,对照组患者予以单纯的甲硝唑栓治疗。乳杆菌活菌胶囊阴道放置,每次1粒,每晚1次,连用10d。甲硝唑栓阴道放置,阴道放置,每次1粒,每晚1次,连用10d。两组患者治疗期间及复查前禁止性生活,避免冲洗阴道及使用抗生素和微生态制剂。观察两组患者治疗停药后2周的临床疗效,并比较随访3个月及6个月内的复发率。结果治疗停药后2周,观察组的临床总有效率为95．45％,明显高于对照组的81．82％（χ2=4．06,P〈0．05）。治疗后进行随访,观察组的3个月及6个月内复发率分别为7．14％和16．67％,均明显低于对照组的25．00％和38．89％（χ2=4．75和4．87,P〈0．05）。结论乳杆菌活菌胶囊联合甲硝唑栓治疗细菌性阴道病具有较好的疗效,并降低其复发率,具有治疗与预防细菌性阴道病的双重作用。     

HPV感染患者阴道微生态、Th17/Treg细胞及相关细胞因子表达分析CSCD

目的 分析人乳头瘤病毒（HPV）感染患者阴道微生态、辅助性T细胞17(Th17)/调节性T细胞（Treg）及相关细胞因子表达情况,为该类患者的治疗提供参考。方法 选取2020年5月至2022年6月厦门大学附属妇女儿童医院收治的HPV感染患者108例作为研究组,另选取我院同期健康体检者108例作为对照组。两组受试者均进行HPV筛查、阴道菌群检测以及阴道微生态检测,采用流式细胞仪检测Th17/Treg细胞;采用酶联免疫吸附法（ELISA）检测白细胞介素-6(IL-6)、 IL-10和IL-17水平;采用Spearman法分析HPV感染患者阴道菌群和Th17/Treg细胞及相关细胞因子的相关性。结果 HPV共检出9种亚型,主要以HPV 16和HPV 18为主。研究组患者阴道乳杆菌阳性率显著低于对照组,衣原体、解脲支原体、滴虫和细菌性阴道病阳性率均显著高于对照组（均P<0.05）。研究组患者阴道pH>4.5、阴道菌群密集度Ⅱ～Ⅳ级、阴道菌群多样性Ⅱ～Ⅳ级和微生态失调率均显著高于对照组（均P<0.05）。研究组患者Th17/Treg、IL-6、IL-10和IL-17水平显著高于对照组（均P<0.05）。Spearman相关性分析显示,阴道中乳杆菌与Th17/Treg、IL-6、IL-10和IL-17水平均呈负相关;衣原体、解脲支原体、滴虫和细菌性阴道病与Th17/Treg、IL-6、IL-10和IL-17水平均呈正相关（均P<0.05）。结论 HPV感染患者存在阴道微生态失调,而且Th17/Treg细胞、IL-6、IL-10和IL-17水平均异常升高。     

定君生治疗复发性细菌性阴道病106例临床观察

目的探讨复发性细菌性阴道病治疗方法。方法选择212例复发性细菌性阴道病病例,随机分为2组,治疗组用甲硝唑阴道泡腾片联合定君生治疗,对照组单用甲硝唑阴道泡腾片治疗。结果2组疗效相似,治疗组复发率明显低于对照组。结论乳杆菌治疗复发性细菌性阴道病,疗效等同于抗生素,但不会产生耐药性和副作用,维持正常的微生态平衡,防治复发。     

凝结芽孢杆菌活菌片联合甲硝唑栓治疗细菌性阴道病的临床观察

目的观察凝结芽孢杆菌活菌片(商品名:爽舒宝)联合甲硝唑栓治疗细菌性阴道病的临床疗效。方法选取细菌性阴道病患者108例随机分为观察组和对照组,每组54例。两组患者均以甲硝唑栓放入阴道治疗,观察组在此基础上,口服凝结芽孢杆菌活菌片,首次6片,以后3片/次,3次/d,连用14d。观察两组患者用药后的临床疗效及不良反应,并比较治疗后随访半年内的复发率。结果观察组患者临床总有效率(90.7%)明显高于对照组(74.1%)(P0.05),治疗期间均未见明显的药物不良反应。治疗后随访半年,观察组的复发率(14.3%)明显低于对照组(32.5%)(P0.05)。结论凝结芽孢杆菌活菌片联合甲硝唑栓治疗细菌性阴道病疗效显著,能降低复发率,值得临床推广应用。     

乳杆菌阴道泡腾片与甲硝唑治疗细菌性阴道炎的疗效比较

目的观察乳杆菌阴道泡腾片治疗细菌性阴道炎的疗效。方法采用双盲、随机对照的方法,在4家医院的妇产科门诊将232例患者分成试验组(n=116)和对照组(n=116)。试验组用药为乳杆菌阴道泡腾片、对照组用药为甲硝唑阴道泡腾片,阴道放置,每晚1片,疗程7 d。治疗前后分别进行临床症状评分、测阴道分泌物pH、做线索细胞和胺试验检查,进行总有效率评定。结果经2种药物治疗后所有患者临床症状均明显减轻,治疗前后自身比较差异有显著性(P<0.01);80%以上的患者呈现线索细胞转(-)、胺试验转(-),超过一半的患者阴道分泌物pH低于4.5;临床治疗总有效率分别为74.78%和83.33%。2种药物组间比较治疗效果差异无显著性(P>0.05)。结论阴道补充乳杆菌与使用甲硝唑治疗产生了相似的效果,有可能成为新的治疗细菌性阴道炎的方法。     

乳杆菌活菌胶囊联合甲硝唑治疗细菌性阴道病的临床疗效

目的观察乳杆菌活菌胶囊联合甲硝唑局部用药治疗细菌性阴道病的临床疗效。方法 228例病例随机分为三组,观察组76例,对照组A 76例,对照组B 76例。观察组在阴道放置甲硝唑片0.4g,每晚1次,连用7d后再在阴道放置乳杆菌活菌胶囊l粒,每晚1次,连用5d;对照组A口服甲硝唑片0.4g,每天2次,连用7d后再在阴道放置乳杆菌活菌胶囊l粒,每晚1次,连用5d;对照组B在阴道放置甲硝唑片0.4g,每晚1次,连用7d。观察治疗后三组总有效率、药物不良反应及复发情况。结果三组患者的总有效率比较差异无统计学意义(92.11%vs 93.42%vs 90.79%)(χ2=0.362,P0.05);3个月后复发情况,观察组与对照组A比较差异无统计学意义(14.47%vs 13.16%)(χ2=0.055,P0.05),对照组B分别与观察组及对照组A比较差异均有统计学意义(34.21%vs 14.47%;34.21%vs 13.16%)(χ21=8.038,P0.01;χ22=9.318,P0.01);治疗后药物不良反应,观察组与对照组B比较差异无统计学意义(2/76 vs 1/76)(χ2=0,P0.05),对照组A分别与观察组及对照组B比较差异均有统计学意义(10/76 vs 2/76;10/76 vs 1/76)(χ21=4.433,P0.05;χ22=6.272,P0.05)。结论乳杆菌活菌胶囊联合甲硝唑局部用药治疗细菌性阴道病疗效快,副反应小,有利于恢复阴道微生态平衡,预防复发。     

利奈唑胺对肾功能不全G~+感染患者血小板减少的相关性研究

目的:分析利奈唑胺对肾功能不全G+患者血小板减少的关系。方法:回顾性分析92例应用利奈唑胺治疗的革兰阳性球菌感染患者的临床资料,根据是否伴有肾功能不全分为肾功能不全组(33例),正常组(59例),检测用药前、用药后血小板计数,观察停药后血小板计数恢复正常时间及不良反应发生情况。结果:肾功能不全组治疗后血小板计数显著低于治疗前及正常组(P0.01),正常组治疗前、后血小板计数比较无统计学意义(P0.05);肾功能不全组血小板减少发生率高于正常组(P0.05);停药后正常组血小板恢复正常时间短于肾功能不全组(P0.01);肾功能不全组血红蛋白下降率高于正常组(P0.05),其余不良反应发生率比较差异无统计学意义(P0.05)。结论:感染患者肾功能可影响利奈唑胺所致血小板减少发生率,肾功能不全患者在应用利奈唑胺时应定期监测血小板计数。     

Effect of Pretreatment with Carbimazole in Patients with Thyrotoxicosis Subsequently Treated with Radioactive Iodine

Preliminary treatment with carbimazole in a series of 181 patients with thyrotoxicosis selected for treatment with radioactive iodine did not make any significant difference to the subsequent response to ¹³¹I therapy.     

Appearance of enterotoxigenic Escherichia coli in piglets with diarrhea in connection with feed changes

Twelve weaned piglet (3-week-old) were divided into three groups according to time of feed change and observed for diarrhea during the time they were 3 to 8 weeks of age. A total of 553 strains of Escherichia coli were isolated from rectal fecal samples and examined for heat-labile (LT) and heat-stable (ST) enterotoxins, pilus antigens (K88, K99, and 987P), hemolysin (Hly), raffinose utilization (Raf) and drug resistance. Enterotoxins and/or hemolytic E. coli strains appeared in the rectal feces of 5- to 6-week-old piglets with diarrhea in connection with feed change and changing temperatures. Most of the isolates showed multiple drug resistance to sulfonamides (Sa), streptomycin (Sp), ampicillin, and/or mercury. Enterotoxigenic E. coli isolates represented four phenotypes: K88+.LT+.Hly+.Raf+.(SaSmCpTcKmSp) (12 strains), K99+.ST+.Raf+.(TcKm) (7 strains), ST+.Raf+.(TcKm) (7 strains), and ST.+(SaSmKm) (25 strains). The drug resistance determinants were transferable concurrently and some of them mobilized the determinants for K88, LT, Hly, and Raf to an E. coli C strain.     

Immunologic correction with immunoglobulin of toxemia with exicosis in infants with acute intestinal infections]

The clinical course of acute intestinal infections complicated by toxicosis and exicosis was studied in 150 infants undergoing multimodality therapy, including natural human immunoglobulin for intravenous injections. The use of the new complex in the treatment of intestinal toxicoses was accompanied by increasing host immunological reactivity within short periods and decreasing of the treatment duration by 5.0 +/- 1.3 days; there were no persisting and chronic forms of the diseases and fatal outcomes. It was concluded that the use of the immunoglobulin for intravenous injections in the multimodality therapy of intestinal toxicoses in infants made it possible to prevent death in complicated intestinal infections and at the same time to accelerate their recovery.     

Decrease in scale invariance of activity fluctuations with aging and in patients with suprasellar tumors

Motor activity in healthy young humans displays intrinsic fluctuations that are scale-invariant over a wide range of time scales (from minutes to hours). Human postmortem and animal lesion studies showed that the intact function of the suprachiasmatic nucleus (SCN) is required to maintain such scale-invariant patterns. We therefore hypothesized that scale invariance is degraded in patients treated for suprasellar tumors that compress the SCN. To test the hypothesis, we investigated 68 patients with nonfunctioning pituitary macroadenoma and 22 patients with craniopharyngioma, as well as 72 age-matched healthy controls (age range 21.0–70.6 years). Spontaneous wrist locomotor activity was measured for 7 days with actigraphy, and detrended fluctuation analysis was applied to assess correlations over a range of time scales from minutes to 24 h. For all the subjects, complex scale-invariant correlations were only present for time scales smaller than 1.5 h, and became more random at time scales 1.5–10 h. Patients with suprasellar tumors showed a larger decrease in correlations at 1.5–10 h as compared to healthy controls. Within healthy subject, gender and age >33 year were associated with attenuated scale invariance. Conversely, activity patterns at time scales between 10 and 24 h were significantly more regular than all other time scales, and this was mostly associated with age.

In conclusion, scale invariance is degraded in healthy subjects at the ages of >33 year as characterized by attenuation of correlations at time scales 1.5–10 h. In addition, scale invariance was more degraded in patients with suprasellar tumors as compared to healthy subjects.